PL4303583T3 - Inhibitory CSF1R do stosowania w leczeniu guzów olbrzymiokomórkowych błony maziowej i pochewki ścięgnistej - Google Patents

Inhibitory CSF1R do stosowania w leczeniu guzów olbrzymiokomórkowych błony maziowej i pochewki ścięgnistej

Info

Publication number
PL4303583T3
PL4303583T3 PL23195809.1T PL23195809T PL4303583T3 PL 4303583 T3 PL4303583 T3 PL 4303583T3 PL 23195809 T PL23195809 T PL 23195809T PL 4303583 T3 PL4303583 T3 PL 4303583T3
Authority
PL
Poland
Prior art keywords
treating
giant cell
cell tumors
tenosynovial giant
csf1r inhibitors
Prior art date
Application number
PL23195809.1T
Other languages
English (en)
Inventor
Daniel L. Flynn
Bryan D. Smith
Rodrigo Ruiz Soto
Keisuke Kuida
Original Assignee
Deciphera Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals, Llc filed Critical Deciphera Pharmaceuticals, Llc
Publication of PL4303583T3 publication Critical patent/PL4303583T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7153—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons or colony-stimulating factors [CSF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL23195809.1T 2018-12-28 2019-12-23 Inhibitory CSF1R do stosowania w leczeniu guzów olbrzymiokomórkowych błony maziowej i pochewki ścięgnistej PL4303583T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786105P 2018-12-28 2018-12-28
US201962926341P 2019-10-25 2019-10-25
US201962933830P 2019-11-11 2019-11-11

Publications (1)

Publication Number Publication Date
PL4303583T3 true PL4303583T3 (pl) 2025-11-17

Family

ID=69191281

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23195809.1T PL4303583T3 (pl) 2018-12-28 2019-12-23 Inhibitory CSF1R do stosowania w leczeniu guzów olbrzymiokomórkowych błony maziowej i pochewki ścięgnistej
PL19842712.2T PL3902547T3 (pl) 2018-12-28 2019-12-23 Inhibitory CSF1R do stosowania w leczeniu nowotworu złośliwego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19842712.2T PL3902547T3 (pl) 2018-12-28 2019-12-23 Inhibitory CSF1R do stosowania w leczeniu nowotworu złośliwego

Country Status (24)

Country Link
US (4) US11103507B2 (pl)
EP (3) EP3902547B1 (pl)
JP (2) JP7626702B2 (pl)
KR (1) KR20210119411A (pl)
CN (4) CN113453684B (pl)
AU (2) AU2019416117B2 (pl)
BR (1) BR112021012812A2 (pl)
CA (1) CA3124112A1 (pl)
DK (2) DK4303583T3 (pl)
ES (1) ES2964489T3 (pl)
FI (2) FI4303583T3 (pl)
HR (2) HRP20251261T1 (pl)
HU (1) HUE065492T2 (pl)
IL (1) IL284199A (pl)
LT (2) LT3902547T (pl)
MX (2) MX2021007927A (pl)
PL (2) PL4303583T3 (pl)
PT (2) PT3902547T (pl)
RS (2) RS67303B1 (pl)
SG (1) SG11202105747XA (pl)
SI (2) SI4303583T1 (pl)
SM (2) SMT202300468T1 (pl)
TW (1) TWI873113B (pl)
WO (1) WO2020139828A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
LT3902547T (lt) 2018-12-28 2024-01-25 Deciphera Pharmaceuticals, Llc Csf1r inhibitoriai, skirti panaudoti vėžio gydymui
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
WO2022063134A1 (zh) * 2020-09-23 2022-03-31 中国科学院上海药物研究所 Csf1r激酶抑制剂及其用途
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CN113880812A (zh) * 2021-11-17 2022-01-04 上海皓元生物医药科技有限公司 一种csf-ir抑制剂的制备方法
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Ｒａｆ激酶抑制劑及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024059508A2 (en) * 2022-09-12 2024-03-21 AmMax Bio, Inc. Treatment of tenosynovial giant cell tumor
EP4483866A1 (en) 2023-06-28 2025-01-01 Makrolife Biotech GmbH Pharmaceutical compositions for the treatment or prevention of cancer
WO2025122952A1 (en) * 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) * 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof
CN118593504B (zh) * 2024-06-03 2025-03-18 北京大学第三医院（北京大学第三临床医学院） 氘可来昔替尼或其盐在制备pvns药物方面的新用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5794047A (en) 1980-12-01 1982-06-11 Ricoh Co Ltd Novel disazo compound and preparation of the same
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
KR100883731B1 (ko) 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20070078121A1 (en) 2004-12-23 2007-04-05 Flynn Daniel L Enzyme modulators and treatments
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2481736A1 (en) 2007-04-20 2012-08-01 Deciphera Pharmaceuticals, LLC. Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US8735584B2 (en) 2008-02-28 2014-05-27 Merck Patent Gmbh Protein kinase inhibitors and use thereof
KR20110099687A (ko) 2008-10-29 2011-09-08 데시페라 파마슈티칼스, 엘엘씨. 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체
WO2011139891A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
BR112012027743A2 (pt) 2010-04-29 2017-03-14 Deciphera Pharmaceuticals Llc ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
KR20140097402A (ko) 2011-11-22 2014-08-06 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9758258B2 (en) 2012-11-29 2017-09-12 Sirkorsky Aircraft Corporation Rotary wing aircraft blade tracking
WO2014145004A1 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
US9133183B2 (en) 2013-03-15 2015-09-15 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145023A1 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
KR102333718B1 (ko) 2013-03-15 2021-12-01 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체
WO2014145029A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
KR20240013846A (ko) * 2013-03-15 2024-01-30 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
KR102374012B1 (ko) 2017-05-24 2022-03-14 아비스코 테라퓨틱스 컴퍼니 리미티드 N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법
KR20220143152A (ko) 2017-05-30 2022-10-24 데시페라 파마슈티칼스, 엘엘씨. 혈소판 유래 성장 인자 수용체 알파의 유전적 이상과 연관된 암 치료를 위한 1-[4-브로모-5-[1-에틸-7-(메틸아미노)-2-옥소-1,2-다이히드로-1,6-나프티리딘-3-일]-2-플루오로페닐]-3-페닐우레아 및 유사체의 용도
NZ763299A (en) 2017-09-14 2025-09-26 Daiichi Sankyo Co Ltd Compound having cyclic structure
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
LT3902547T (lt) * 2018-12-28 2024-01-25 Deciphera Pharmaceuticals, Llc Csf1r inhibitoriai, skirti panaudoti vėžio gydymui
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
TW202300142A (zh) 2021-05-24 2023-01-01 大陸商上海和譽生物醫藥科技有限公司 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用
CN113880812A (zh) 2021-11-17 2022-01-04 上海皓元生物医药科技有限公司 一种csf-ir抑制剂的制备方法
CN116283919A (zh) 2023-03-21 2023-06-23 上海皓元医药股份有限公司 Vimseltinib的新晶型及其制备方法

Also Published As

Publication number Publication date
US11103507B2 (en) 2021-08-31
HRP20231478T1 (hr) 2024-04-26
BR112021012812A2 (pt) 2021-12-07
AU2024205010A1 (en) 2024-08-08
EP4647767A2 (en) 2025-11-12
CN118453610A (zh) 2024-08-09
PT4303583T (pt) 2025-10-28
KR20210119411A (ko) 2021-10-05
US12285430B2 (en) 2025-04-29
NZ776424A (en) 2025-05-02
JP7626702B2 (ja) 2025-02-04
EP4303583A3 (en) 2024-03-27
WO2020139828A1 (en) 2020-07-02
IL284199A (en) 2021-08-31
SI4303583T1 (sl) 2025-11-28
CN118453609A (zh) 2024-08-09
AU2019416117A1 (en) 2021-06-17
DK4303583T3 (da) 2025-10-13
SMT202300468T1 (it) 2024-03-13
CN113453684A (zh) 2021-09-28
US12485120B2 (en) 2025-12-02
US20230414614A1 (en) 2023-12-28
RS67303B1 (sr) 2025-11-28
HUE065492T2 (hu) 2024-05-28
SI3902547T1 (sl) 2024-02-29
HRP20251261T1 (hr) 2025-12-05
SMT202500389T1 (it) 2025-11-10
ES2964489T3 (es) 2024-04-08
FI3902547T3 (fi) 2023-12-05
PT3902547T (pt) 2023-12-04
US11679110B2 (en) 2023-06-20
PL3902547T3 (pl) 2024-02-26
CN113453684B (zh) 2024-05-14
EP3902547B1 (en) 2023-09-20
EP4303583A2 (en) 2024-01-10
LT3902547T (lt) 2024-01-25
MX2024002838A (es) 2024-03-19
FI4303583T3 (fi) 2025-10-15
US20250205237A1 (en) 2025-06-26
AU2024205010B2 (en) 2025-10-30
AU2019416117B2 (en) 2024-05-02
EP3902547A1 (en) 2021-11-03
LT4303583T (lt) 2025-10-27
MX2021007927A (es) 2021-10-26
CN118453608A (zh) 2024-08-09
EP4303583B1 (en) 2025-07-23
JP2022516090A (ja) 2022-02-24
CA3124112A1 (en) 2020-07-02
DK3902547T3 (da) 2023-12-18
TWI873113B (zh) 2025-02-21
SG11202105747XA (en) 2021-07-29
US20200253973A1 (en) 2020-08-13
US20220143018A1 (en) 2022-05-12
TW202041218A (zh) 2020-11-16
RS64993B1 (sr) 2024-01-31
JP2025066790A (ja) 2025-04-23

Similar Documents

Publication Publication Date Title
SI4303583T1 (sl) Zaviralci csf1r za uporabo pri zdravljenju velikoceličnih tumorjih tenosinovije
IL282663A (en) BT1718 for use in cancer treatment
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL272596A (en) Pridopidine for use in the treatment of ALS
IL275075A (en) Phenotypic markers for cell therapy and related methods
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
HUE057175T2 (hu) Sirolimuszt és albumint tartalmazó nanorészecskék hámsejtes daganatok kezelésében történõ alkalmazásra
HUE071527T2 (hu) Tradipitant gasztroparézis kezelésében történõ alkalmazásra
IL265488A (en) Cellular therapy with polarized macrophages for tissue construction
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
PL3458448T3 (pl) Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
SI3293201T1 (sl) Kombinacija zaviralcev adenovirusa in zaviralcev kontrolnih točk za zdravljenje raka
PL3534885T3 (pl) Inhibitory farnezylotransferazy do zastosowania w leczeniu nowotworu
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
IL286949A (en) Mesitantan for use in the treatment of portopulmonary hypertension
PL3801490T3 (pl) Związki do zastosowania w kacheksji nowotworowej
GB201709417D0 (en) Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
HK40052012A (en) Usp19 inhibitors for use in therapy
HK40060258A (zh) 用於治疗癌症的bt1718
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro
HK40003841A (en) Nanoliposomal irinotecan for use in treating small cell lung cancer